Is Antiplatelet Therapy After WATCHMAN Implantation Adequate?

Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation.

BACKGROUND The influences of antiplatelet therapy discontinuation on the risk of stent thrombosis and long-term clinical outcomes after drug-eluting stent implantation have not yet been addressed adequately. METHODS AND RESULTS In an observational study in Japan, 2-year outcomes were assessed in 10 778 patients undergoing sirolimus-eluting stent implantation. Data on status of antiplatelet th...

Double Antiplatelet Therapy After Drug-Eluting Stent Implantation

Ignacio Ferreira-González, MD, PHD,*† Josep R. Marsal, BSC,*†‡ Aida Ribera, PHD,*† Gaietà Permanyer-Miralda, MD, PHD,*† Bruno Garcı́a-Del Blanco, MD,* Gerard Martı́, MD,* Purificación Cascant, RN,*† Mónica Masotti-Centol, MD, PHD,§ Xavier Carrillo, MD, Josepa Mauri, PHD, Nuria Batalla, MD,¶ Eduard Larrousse, MD,# Eva Martı́n, MD,** Antonio Serra, MD,†† José Ramón Rumoroso, MD,‡‡ Rafael Ruiz-Salmer...

Dual antiplatelet therapy after drug-eluting stent implantation: is it time to slacken the reins?

Drug-eluting stents (DES) were introduced in interventional practice more than 10 years ago and rapidly replaced bare-metal stents (BMS) for treatment of coronary artery disease because of their superior capability to reduce the need for restenosis-driven repeat intervention. Soon, it became obvious that besides optimal stenting technique, dual antiplatelet therapy (DAPT), which means the combi...

Is Hesaabdaaree an Adequate Equivalent for Accounting?

Some of the difficulties and misunderstandings that happen in accounting theory, practice, regulation and education are grounded in language and linguistics. As an illustration of this the Persian equivalent of 'accounting' is linguistically analysed to reveal how a mistranslation may cause difficulties in understanding and improving Iranian Accounting. This paper shows how Hesaabdaaree is not ...

Is the Duration of Dual Antiplatelet Therapy after Implantation of Drug-Eluting Stents the Longer the Better?